Multi-Omics Early Detection Platform
Multi-Cancer Early Detection (MCED)
Discovery/Pre-ClinicalActive
Key Facts
Indication
Multi-Cancer Early Detection (MCED)
Phase
Discovery/Pre-Clinical
Status
Active
Company
About PrognomiQ
PrognomiQ is a clinical-stage biotech company with a mission to transform early detection and treatment through its proprietary multi-omics platform. Founded in 2020 as a spinout from Seer Inc., the company leverages unprecedented scale in proteomic data generation, combined with other 'omics' layers, to unlock novel biological insights for diagnostic development. Its strategy is to translate these discoveries into commercial diagnostic tests, positioning it within the competitive early cancer detection landscape. The company is publicly traded, providing capital markets access to fund its ambitious R&D agenda.
View full company profileTherapeutic Areas
Other Multi-Cancer Early Detection (MCED) Drugs
| Drug | Company | Phase |
|---|---|---|
| OneTest for Cancer | 20/20 BioLabs | Commercial |
| miONCO | Xgenera | Pre-clinical |
| Early Cancer Detection | Burning Rock Biotech | R&D/Clinical Studies |